Laboratory Testing for Insulin Resistance Assessment
Order fasting insulin and fasting glucose to calculate HOMA-IR, along with fasting triglycerides and HDL-cholesterol, as these provide the most practical and validated approach to assess insulin resistance in clinical practice.
Primary Testing Strategy
The most clinically useful bloodwork panel includes:
- Fasting plasma glucose (after ≥8 hours fasting)
- Fasting insulin (after ≥8 hours fasting)
- Fasting lipid panel (triglycerides and HDL-cholesterol)
These tests allow calculation of HOMA-IR (Homeostatic Model Assessment of Insulin Resistance), which is the most widely validated surrogate marker for insulin resistance in clinical settings 1, 2. The formula is: HOMA-IR = (fasting insulin in μU/mL × fasting glucose in mmol/L) / 22.5.
Diagnostic Thresholds and Interpretation
HOMA-IR cutoffs for insulin resistance:
- HOMA-IR >4.65 indicates insulin resistance 3
- If BMI >27.5 kg/m², a lower threshold of HOMA-IR >3.60 is diagnostic 3
- These correspond to fasting insulin levels of approximately 20.7 μU/mL and 16.3 μU/mL, respectively 3
Alternative indices using the same bloodwork:
- QUICKI (Quantitative Insulin Sensitivity Check Index) = 1/[log(fasting insulin μU/mL) + log(fasting glucose mg/dL)] - values <0.33 suggest insulin resistance 1, 2
- TyG index (Triglyceride-Glucose index) = ln[fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2] - elevated values indicate insulin resistance 4
- TG/HDL-C ratio - values >3.0 suggest insulin resistance 4
Enhanced Screening Approach
A weighted combination of fasting insulin and triglycerides provides superior sensitivity compared to fasting insulin alone 5. Research demonstrates that using the formula: Mffm/I = exp[2.63 - 0.28ln(insulin) - 0.31ln(triglycerides)] improves screening accuracy while maintaining specificity 5.
Additional Considerations
HbA1c measurement should be included when screening for prediabetes or diabetes risk, as current guidelines recommend HbA1c, fasting plasma glucose, or 2-hour OGTT for screening high-risk individuals 6, 7. While HbA1c doesn't directly measure insulin resistance, values between 5.7-6.4% (39-47 mmol/mol) indicate prediabetes, which is strongly associated with insulin resistance.
Sample handling is critical: Blood should be collected in tubes with citrate buffer glycolytic inhibitor and processed within 15-30 minutes if not immediately analyzed, as sodium fluoride alone is insufficient to prevent glycolysis 7.
Clinical Context
The hyperinsulinemic-euglycemic clamp remains the gold standard for measuring insulin resistance 8, 1, 4, but it is impractical for routine clinical use due to its complexity, invasiveness, and cost. The surrogate markers described above (HOMA-IR, QUICKI, TyG index) have been extensively validated against clamp studies and provide clinically actionable information 1, 2.
Common Pitfalls to Avoid
- Do not rely on fasting glucose alone - it may remain normal despite significant insulin resistance
- Ensure true fasting state (≥8 hours) for accurate results
- Do not use point-of-care glucose or insulin measurements for diagnostic purposes 7
- Recognize that insulin assays lack standardization across laboratories, which can affect HOMA-IR calculations 1
When to Screen
Screen individuals who are overweight (BMI ≥25 kg/m²) with additional risk factors, or anyone ≥35 years of age 6. For children ≥10 years old (or at puberty onset), screen if BMI >85th percentile plus risk factors 6.